SGLT2 Inhibitors in Type 2 Diabetes Management

Mechanism of Action and Available Inhibitors

The American Diabetes Association acknowledges that SGLT2 inhibitors, such as empagliflozin, work by blocking the sodium-glucose co-transporter 2 proteins in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion 1, 2
The European Association for the Study of Diabetes notes that these medications lower the renal threshold for glucose (RTG), promoting glucosuria when blood glucose levels exceed approximately 180 mg/dL, although the exact mechanism is complex and involves multiple pathways 2
The American College of Cardiology recognizes that SGLT2 inhibitors, including dapagliflozin and ertugliflozin, function independently of insulin secretion or action, making them effective regardless of diabetes duration 1, 2, 3

The American Heart Association recommends that SGLT2 inhibitors can reduce HbA1c levels by approximately 0.5% to 1.0%, and also promote weight loss of 1.5 to 3.5 kg 1
The European Society of Cardiology notes that SGLT2 inhibitors can lower systolic blood pressure by 3 to 5 mmHg, and reduce the risk of major cardiovascular adverse events 1, 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that SGLT2 inhibitors can decrease hospitalization rates for heart failure, and have renoprotective effects with reduced progression of diabetic kidney disease 1, 3
The American Diabetes Association acknowledges that SGLT2 inhibitors have a low risk of hypoglycemia when used as monotherapy 1

The FDA warns that rare adverse events associated with SGLT2 inhibitors include diabetic ketoacidosis, acute kidney injury, and bone fractures 1
The European Medicines Agency notes that canagliflozin specifically has been associated with a potential increased risk of lower extremity amputations 1
The National Institute for Health and Care Excellence (NICE) guidelines recommend that dose adjustments are required in patients with moderate renal impairment, and these medications should be discontinued in severe renal impairment 1

The American Neurological Association suggests that recent studies indicate SGLT2 inhibitors may have neuroprotective properties due to the presence of SGLT2 in the Central Nervous System 4, 5
The European Association for the Study of Diabetes notes that potential benefits in cognitive function in patients with type 2 diabetes mellitus are being investigated 4, 5

The American College of Cardiology recommends Canagliflozin for its demonstrated cardiovascular benefits in the CANVAS trials, with a standard dosing of 100 mg or 300 mg once daily 6, 7
The American College of Cardiology suggests that SGLT2 inhibitors, such as Empagliflozin and Canagliflozin, reduce major adverse cardiovascular events (MACE) and heart failure hospitalization, with Empagliflozin specifically reducing cardiovascular death by 38% and all-cause mortality by 32% 7, 8

The American College of Cardiology recommends standard dosing for SGLT2 inhibitors, including Empagliflozin at 10 mg or 25 mg once daily, Canagliflozin at 100 mg or 300 mg once daily, and Dapagliflozin at 10 mg once daily 6

The American College of Cardiology reports that SGLT2 inhibitors significantly reduce cardiovascular mortality, heart‑failure hospitalizations, and slow progression of chronic kidney disease in patients with diabetes, heart failure, or chronic kidney disease. 9

The American College of Cardiology and Pharmacology and Therapeutics note that genital mycotic infections, particularly balanitis, occur more frequently in men than candida vaginitis in women when treated with SGLT2 inhibitors. 9, 10

Pharmacology and Therapeutics indicates that endogenous androgens increase renin concentrations, enhance ACE activity, and up‑regulate the renin‑angiotensin‑aldosterone system. 11, 12
Both the American College of Cardiology and Pharmacology and Therapeutics state that no data exist regarding the effect of SGLT2 inhibitors on testosterone, estradiol, or other sex hormones in either sex. 9, 10

Pharmacology and Therapeutics recommends obtaining baseline serum estradiol and testosterone measurements in male patients when clinically indicated before initiating SGLT2 inhibitor therapy. 11
Pharmacology and Therapeutics advises re‑checking sex‑hormone levels at 3–6 months if there is clinical suspicion of hormonal changes such as gynecomastia, sexual dysfunction, or mood alterations. 11

The American College of Cardiology emphasizes that SGLT2 inhibitors should not be withheld on the basis of theoretical hormonal effects, given their proven mortality and morbidity benefits in diabetes, heart failure, and chronic kidney disease. 9
The American College of Cardiology clarifies that the increased risk of balanitis in men is attributable to glucosuria‑driven candida growth, not to alterations in sex‑hormone levels. 9